C9029 Guselkumab Injection HCPCS Reimbursement

HCPCS Level II code C9029 denotes the drug unit for guselkumab at 1 mg per billing unit. Guselkumab is a monoclonal antibody used in specialty dermatology and immunology indications; coding the drug by unit is central to accurate drug cost reporting, reimbursement, and inventory management across outpatient infusion and injection sites. Nationally, precise HCPCS Level II coding for high-cost biologics like guselkumab affects provider billing, payer coverage decisions, and patient cost-sharing.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of code purpose and clinical context, common payer coverage considerations, typical sites of service where the code is billed, and which benchmarks or policy updates are commonly relevant for high-cost injectable biologics. The publication highlights common billing practices around unit-based drug codes, how payers typically approach coverage and reimbursement for specialty biologics, and operational considerations for providers and billing teams.

Data not available in the input prevents inclusion of payer-specific rates, modifiers beyond those listed elsewhere, associated taxonomies, ICD-10 pairings, and related codes; where available, those items are addressed in separate sections of the full publication.

Billing Code Overview

HCPCS Level II code C9029 describes Injection, guselkumab, 1 mg. This code represents the drug product by unit strength and is used for billing administration of guselkumab measured per milligram. The service type derived from the description is drug administration / injectable biologic. The typical site of service for billing this HCPCS Level II drug code is outpatient infusion or injection settings, including physician offices, hospital outpatient departments, and specialty infusion centers.

Data not available in the input.

Clinical Context

A typical patient is an adult with moderate to severe plaque psoriasis or active psoriatic arthritis who has been evaluated by a dermatologist or rheumatologist and is considered a candidate for biologic therapy. The patient presents to an outpatient infusion/ injection clinic or office-based procedure room for administration of subcutaneous guselkumab. After verification of identity, allergies, and current medications, the clinician confirms the indication and documents baseline disease activity and prior biologic therapies. The medication, billed as C9029 for guselkumab, 1 mg, is prepared in the pharmacy or clinic and labeled for the patient; dosing is weight-independent per product labeling. The injection is administered subcutaneously, typically in the upper arm, abdomen, or thigh. Observation for immediate adverse reactions follows for a brief period (commonly 15–30 minutes) with vital signs recorded. Documentation includes the lot number, syringe or vial amount administered, route (subcutaneous), site, and any immediate reactions. For maintenance therapy, follow-up scheduling and monitoring plans for infection risk and laboratory testing are documented in the medical record.

Coding Specifications

Modifier	Description	When to Use
`51`	Multiple Procedures	When multiple distinct procedures or services are billed on the same day and payer policy requires indication of multiple procedure reduction.

Taxonomy Code	Specialty	Notes
`207N00000X`	Dermatology	Dermatologists most commonly prescribe and oversee guselkumab for plaque psoriasis.
`207R00000X`	Rheumatology	Rheumatologists prescribe guselkumab for psoriatic arthritis when indicated.
`208D00000X`	Allergy & Immunology	Allergists/immunologists may manage biologic therapy for immune-mediated skin or joint disease.
`363L00000X`	Family Medicine	Primary care physicians may administer and coordinate biologic injections in office settings.
`261QM0800X`	Nurse Practitioner	Advanced practice providers frequently perform patient assessment and administer injections in outpatient clinics.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L40.0`	Psoriasis vulgaris	Primary indication for guselkumab for moderate to severe plaque psoriasis.
`L40.5`	Arthropathic psoriasis	Indicates psoriatic arthritis features where biologic therapy may be indicated.
`M07.0`	Distal interphalangeal psoriatic arthropathy	A psoriatic arthritis subtype that may be treated with biologic agents.
`M07.3`	Psoriatic spondylitis	Inflammatory axial involvement in psoriatic disease treated by rheumatology with biologics.
`L40.8`	Other psoriasis	Less common psoriasis variants that may still warrant systemic biologic therapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Common charge for the administration of a subcutaneous biologic like guselkumab when billed separately from the drug itself.
`99024`	Postoperative follow-up visit, included in global service (use when appropriate)	Not typically used for routine biologic injections; listed for completeness where follow-up visit billing rules apply.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M code for evaluation and management visits associated with biologic therapy assessments when billed same day as injection (use with modifier `25` if billed separately).
`85025`	Complete blood count (CBC) automated, with differential	Lab testing commonly ordered prior to or during biologic therapy to monitor for infection risk and baseline labs.
`80053`	Comprehensive metabolic panel	Routine laboratory monitoring for patients on systemic biologic therapy.

OpenPayer

Summary & Overview

HCPCS Level II C9029: Injection, guselkumab 1 mg